Rondo Therapeutics dosed first patient in Phase 1 trial for bispecific antibody RNDO-564.
Rondo Therapeutics is a clinical-stage biotechnology company focused on developing innovative bispecific antibodies to target and eliminate solid tumors while maximizing efficacy and minimizing side effects
Rondo Therapeutics is a clinical-stage biotechnology company focused on developing innovative bispecific antibodies to target and eliminate solid tumors while maximizing efficacy and minimizing side effects.